Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

484 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Significance of molecular diagnostics for therapeutic decision-making in recurrent glioma.
Blobner J, Dengler L, Blobner S, Eberle C, Weller J, Teske N, Karschnia P, Rühlmann K, Heinrich K, Ziemann F, Greif PA, Jeremias I, Wuerstlein R, Hasselmann K, Dorostkar M, Harter PN, Quach S, Stoecklein V, Albert NL, Niyazi M, Tonn JC, Thon N, Christoph Westphalen B, von Baumgarten L. Blobner J, et al. Among authors: heinrich k. Neurooncol Adv. 2023 May 12;5(1):vdad060. doi: 10.1093/noajnl/vdad060. eCollection 2023 Jan-Dec. Neurooncol Adv. 2023. PMID: 37287694 Free PMC article.
Precision Oncology in Pancreatic Cancer: Experiences and Challenges of the CCCMunichLMU Molecular Tumor Board.
Dorman K, Zhang D, Heinrich K, Reeh L, Weiss L, Haas M, Beyer G, Rössler D, Goni E, Renz BW, D'Haese JG, Kunz WG, Seidensticker M, Corradini S, Niyazi M, Ormanns S, Kumbrink J, Jung A, Klauschen F, Werner J, Mayerle J, von Bergwelt-Baildon M, Boeck S, Heinemann V, Westphalen CB. Dorman K, et al. Among authors: heinrich k. Target Oncol. 2023 Mar;18(2):257-267. doi: 10.1007/s11523-023-00950-0. Epub 2023 Feb 28. Target Oncol. 2023. PMID: 36853374 Free PMC article.
Implementing precision oncology for sarcoma patients: the CCCLMUmolecular tumor board experience.
Berclaz LM, Burkhard-Meier A, Lange P, Di Gioia D, Schmidt M, Knösel T, Klauschen F, von Bergwelt-Baildon M, Heinemann V, Greif PA, Westphalen CB, Heinrich K, Lindner LH. Berclaz LM, et al. Among authors: heinrich k. J Cancer Res Clin Oncol. 2023 Nov;149(15):13973-13983. doi: 10.1007/s00432-023-05179-y. Epub 2023 Aug 5. J Cancer Res Clin Oncol. 2023. PMID: 37542550 Free PMC article.
A Retrospective Analysis of Biliary Tract Cancer Patients Presented to the Molecular Tumor Board at the Comprehensive Cancer Center Munich.
Zhang D, Dorman K, Heinrich K, Weiss L, Boukovala M, Haas M, Greif PA, Ziemann F, Beyer G, Roessler D, Goni E, Renz B, D'Haese JG, Kunz WG, Seidensticker M, Corradini S, Niyazi M, Ormanns S, Kumbrink J, Jung A, Mock A, Rudelius M, Klauschen F, Werner J, Mayerle J, von Bergwelt-Baildon M, Boeck S, Heinemann V, Westphalen CB. Zhang D, et al. Among authors: heinrich k. Target Oncol. 2023 Sep;18(5):767-776. doi: 10.1007/s11523-023-00985-3. Epub 2023 Aug 18. Target Oncol. 2023. PMID: 37594677 Free PMC article.
Genetics and beyond: Precision Medicine Real-World Data for Patients with Cervical, Vaginal or Vulvar Cancer in a Tertiary Cancer Center.
Kraus FBT, Sultova E, Heinrich K, Jung A, Westphalen CB, Tauber CV, Kumbrink J, Rudelius M, Klauschen F, Greif PA, König A, Chelariu-Raicu A, Czogalla B, Burges A, Mahner S, Wuerstlein R, Trillsch F. Kraus FBT, et al. Among authors: heinrich k. Int J Mol Sci. 2024 Feb 16;25(4):2345. doi: 10.3390/ijms25042345. Int J Mol Sci. 2024. PMID: 38397025 Free PMC article.
Quo vadis precision oncology?
Heinrich K, Westphalen CB. Heinrich K, et al. J Cancer Res Clin Oncol. 2023 Jan;149(1):3-4. doi: 10.1007/s00432-022-04478-0. Epub 2023 Jan 13. J Cancer Res Clin Oncol. 2023. PMID: 36637503 Free PMC article. No abstract available.
Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: an AGEO European Cohort.
Taïeb J, Sayah L, Heinrich K, Kunzmann V, Boileve A, Cirkel G, Lonardi S, Chibaudel B, Turpin A, Beller T, Hautefeuille V, Vivaldi C, Mazard T, Bauguion L, Niger M, Prager GW, Coutzac C, Benedikt Westphalen C, Auclin E, Pilla L. Taïeb J, et al. Among authors: heinrich k. Eur J Cancer. 2023 Jul;188:90-97. doi: 10.1016/j.ejca.2023.04.012. Epub 2023 Apr 23. Eur J Cancer. 2023. PMID: 37229836
Gemcitabine and nab-paclitaxel combined with afatinib in metastatic pancreatic cancer - Results of a phase 1b clinical trial.
Zhang D, Benedikt Westphalen C, Quante M, Waldschmidt DT, Held S, Kütting F, Dorman K, Heinrich K, Weiss L, Boukovala M, Haas M, Boeck S, Heinemann V, Probst V. Zhang D, et al. Among authors: heinrich k. Eur J Cancer. 2024 Apr;201:113926. doi: 10.1016/j.ejca.2024.113926. Epub 2024 Feb 15. Eur J Cancer. 2024. PMID: 38401449 Free article. Clinical Trial.
Checkpoint Inhibitor Monotherapy in Potentially Trial-Eligible or Trial-Ineligible Patients With Metastatic NSCLC in the German Prospective CRISP Registry Real-World Cohort (AIO-TRK-0315).
Griesinger F, Sebastian M, Brueckl WM, Hummel HD, Jaeschke B, Kern J, Wesseler C, Jänicke M, Fleitz A, Zacharias S, Hipper A, Groth A, Weichert W, Dörfel S, Petersen V, Schröder J, Wilke J, Eberhardt WEE, Thomas M; CRISP Registry Group. Griesinger F, et al. JTO Clin Res Rep. 2023 Dec 25;5(4):100626. doi: 10.1016/j.jtocrr.2023.100626. eCollection 2024 Apr. JTO Clin Res Rep. 2023. PMID: 38586301 Free PMC article.
Primary resistance to immunotherapy in patients with a dMMR/MSI metastatic gastrointestinal cancer: who is at risk? An AGEO real-world study.
Flecchia C, Auclin E, Alouani E, Mercier M, Hollebecque A, Turpin A, Mazard T, Pernot S, Dutherage M, Cohen R, Borg C, Hautefeuille V, Sclafani F, Ben-Abdelghani M, Aparicio T, De La Fouchardière C, Herve C, Perkins G, Heinrich K, Kunzmann V, Gallois C, Guimbaud R, Tougeron D, Taieb J. Flecchia C, et al. Among authors: heinrich k. Br J Cancer. 2024 Feb;130(3):442-449. doi: 10.1038/s41416-023-02524-3. Epub 2023 Dec 15. Br J Cancer. 2024. PMID: 38102227
484 results